# About CJC + Ipa Store: An Independent Almanac of the CJC-1295 Ipamorelin Literature

> CJC-1295 ipamorelin: about this site. CJC + Ipa Store is an independent editorial almanac of the peer-reviewed secretagogue literature. Not a clinic, not a vendor, not a prescription.

## What This Site Is

CJC + Ipa Store is an independent editorial project that publishes summaries of the peer-reviewed research literature on CJC-1295 ipamorelin. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The "store" in the domain name is an archive reference — the holdings of a curated library of studies, sorted like a folk-art almanac. This site does not sell, fulfill, or process orders for any compound.

## Editorial Methodology

Every quantitative claim on this site is sourced to a numbered citation in the References index. Citations are drawn from PubMed-indexed journals, ClinicalTrials.gov, and peer-reviewed pharmacology and endocrinology literature. The research record covers findings from 1998 through 2025. All claims are attributed to the species and study design in which they were measured.

This site does not cite preprints, promotional literature, manufacturer white papers, or community anecdotes. Where the peer-reviewed evidence base is thin, the site states the gap explicitly.

## Regulatory Status of CJC-1295 and Ipamorelin

Neither CJC-1295 nor ipamorelin holds FDA approval for any human indication. CJC-1295 (with DAC) reached Phase I/II-context human studies published in 2006–2009 through ConjuChem Inc. Ipamorelin was studied in Phase I/II for postoperative ileus (NCT00672074) and in a small Phase I safety study. Neither compound has completed Phase III trials.

Both compounds appear on the WADA Prohibited List: CJC-1295 as a GHRH analog (Section S2) and ipamorelin as a growth hormone secretagogue (GHS-R1a agonist, Section S2). As of December 2024 FDA PCAC briefing documents, CJC-1295 acetate forms were proposed not to be included on the 503A Bulks List. Ipamorelin's compounding status is under ongoing evaluation.

## Editorial Disclaimer

This site is an editorial digest of peer-reviewed scientific literature. It is not a source of medical advice, clinical guidance, or treatment recommendations. No content on this site should be construed as recommending the acquisition, preparation, or administration of any compound. Consult a qualified healthcare professional for any medical concern.

---

Twenty-two studies across six species, indexed as a folk-almanac of the CJC-1295 ipamorelin literature — no clinic behind the cordel, no vendor behind the broadside.